Applied Filters
SCOTUS invites govt comment on Teva clash
Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
MSD prevails in diabetes drug dispute with Mylan
MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.
Federal Circuit denies Novartis’ bid to halt generics
Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Swiss pharma company reveals SCOTUS appeal plans
Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big pharma firm settles HIV drug disputes with generic makers
Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.
Generic maker urges review of $235m skinny label decision
A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.
Novartis sued over blockbuster heart failure drug
Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Gilead must face pay-for-delay suit
Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Chugai settles cancer drug patent dispute with US firm
Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Pharma unit could get green light to launch IBS generic
Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
